Aug 11, 2020
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
Jun 16, 2020
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
Jun 15, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML
Jun 09, 2020
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation
May 29, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
May 28, 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
May 19, 2020
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
May 13, 2020
Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
May 06, 2020
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
Apr 22, 2020
Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD
Apr 08, 2020
Trovagene to Present at the 19th Annual Needham Healthcare Conference
Apr 01, 2020
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
Feb 27, 2020
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
Feb 13, 2020
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
Jan 29, 2020
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
Jan 21, 2020
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
Dec 04, 2019
Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)
Nov 14, 2019
Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®
Nov 07, 2019
Trovagene Announces Third Quarter 2019 Results and Highlights
Nov 06, 2019
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting